• Events
  • Webinar: The Global Response to AMR: Momentum, success...
Webinar - Event date: 18 Nov 2020

The Global Response to AMR: Momentum, success and critical gaps

On Wednesday 18 November 2020, Damiano De Felice, Director of Strategy at the Access to Medicine Foundation, joined a virtual panel discussion hosted by the Wellcome Trust to launch their AMR Landscape analysis titled "The Global Response to AMR - Momentum, success, and critical gaps". 

Over the last year, Wellcome has mapped the global response to AMR to identify progress made since the UN High-Level Meeting on AMR held in 2016. The analysis captures the views of over 150 experts and reviewed more than 250 documents and aims to bring all this together in a critical path for what the global response to AMR could look like now, and beyond 2030.

During the webinar, panelists ran through the key findings of the analysis and participated in a discussion about the relevance of the report as well as possible future uses for the work. In his remarks, Damiano congratulated Wellcome's team for its courage to prioritise certain themes over others and highlighted the alignment between the work of the Access to Medicine Foundation and Wellcome's revised approach, which focuses on advancing a sustainable pipeline for antibiotics to protect global public health and fostering the mobilisation of government-led action on AMR.

Other speakers included:

  • Tim Jinks, Head of Drug-Resistant Infection Programme, Wellcome Trust
  • Lindsay Denny, Health advisor, Global Water 2020
  • Junxia Song, Senior Animal Health Officer, Food & Agriculture Organization (FAO)
  • Jyoti Joshi, Head of South Asia, The Center For Disease Dynamics, Economics & Policy, CDDEP 

On 6 October 2020, the Access to Medicine Foundation published the methodology for the 2021 Antimicrobial Resistance Benchmark. The methodology covers numerous themes prioritised by Wellcome's report, including R&D for new antibiotics and vaccines, appropriate access and stewardship. Wellcome's report has multiple references to the findings of the 2020 Antimicrobial Resistance Benchmark.

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.

Back to top |